Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Arca Biopharma Inc

(NASDAQ: ABIO)
Add to Portfolio
-0.15 (-2.80%)
as of Feb 19, 2020

Last 5.20
Change -0.15 (-2.80%)
Open 5.55
Prev. Close 5.35
Today's Range
4.92
5.55
52wk Range
4.89
20.45
Volume 86,000
Avg Volume 26,725
Sector SIC-2835 In Vitro & In Vivo Diagnostic Substances

Perfomance Comparison

Name Today 3-Month 1-Year
ABIO -2.80% -4.06% -25.93%
DJIA +0.40% +6.03% +13.35%
S&P 500 +0.47% +8.62% +21.81%

Key Statistics

Annual EPS -4.45
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 8,820
Weighted Alpha -51.09
Standard Deviation -0.95
Profit Margin N/A
Beta 1.90

Growth Rates

YTD -8.94%
1-Year -35.39%
3-Year -88.48%
5-Year -93.93%
10-Year -99.76%

Opinion

Sell Hold Buy

Recent Headlines

ARCA biopharma Announces Fiscal Year 2019 Financial

GlobeNewswire via COMTEX - Tue Feb 18, 04:30PM EST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended (full story)
ABIO: 5.20 (-0.15)

ARCA Biopharma Announces Third Quarter 2019 Financial

GlobeNewswire via COMTEX - Wed Nov 06, 04:10PM EST
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter end(full story)
ABIO: 5.20 (-0.15)

ARCA Biopharma President and CEO Dr. Michael Bristow

GlobeNewswire via COMTEX - Thu Sep 12, 08:30AM EDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael Bristow, President (full story)
ABIO: 5.20 (-0.15)

Arca Biopharma Announces Gencaro Atrial Fibrillation

GlobeNewswire via COMTEX - Wed Sep 11, 08:30AM EDT
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that Gencaro atrial fibrillation cli(full story)
ABIO: 5.20 (-0.15)

INVESTOR ACTION NOTICE: The Schall Law Firm Announces

GlobeNewswire via COMTEX - Wed Aug 21, 09:49AM EDT
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. ("Abiomed" or "the Company") (NASDAQ: ABMD) for violations of §§10(b)(full story)
ABIO: 5.20 (-0.15), ABMD: 167.90 (-1.10)